Evidence map›Paper›PMID 34557099›Full record

ArticleFrontiers in pharmacology2021

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews.

Nikolaos Pyrgidis, Ioannis Mykoniatis, Anna-Bettina Haidich, Maria Tirta, Persefoni Talimtzi, Dimitrios Kalyvianakis, Andreas Ouranidis, Dimitrios Hatzichristou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Tadalafil in patients on antihypertensive medications: Does safety remain an issue?Journal of clinical hypertension (Greenwich, Conn.) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Nikolaos PyrgidisInstitute for the Study of Urological Diseases, Thessaloniki, Greece.
Ioannis MykoniatisInstitute for the Study of Urological Diseases, Thessaloniki, Greece.
Anna-Bettina HaidichDepartment of Hygiene, Social-Preventive Medicine and Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Maria TirtaInstitute for the Study of Urological Diseases, Thessaloniki, Greece.
Persefoni TalimtziDepartment of Hygiene, Social-Preventive Medicine and Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitrios KalyvianakisInstitute for the Study of Urological Diseases, Thessaloniki, Greece.
Andreas OuranidisDepartment of Pharmaceutical Technology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitrios HatzichristouInstitute for the Study of Urological Diseases, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRInstitute for the Study of Urologic Diseases · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

erectile dysfucntionmeta-analysisoverview of systematic reviewsphosphodiesterase type 5 (PDE5) inhibitorssexual dysfuction

Identifiers

PMID34557099
PMCPMC8452927
OpenAlexW3197616241

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.